Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells

Marc R. Theoret, Cyrille J. Cohen, Azam V. Nahvi, Lien T. Ngo, Kimberly B. Suri, Daniel J. Powell, Mark E. Dudley, Richard A. Morgan, Steven A. Rosenberg

Research output: Contribution to journalArticle

Abstract

Tumor suppressor p53 is reported to be an attractive immunotherapy target because it is mutated in approximately half of human cancers, resulting in inactivation and often an accumulation of the protein in the tumor cells. Only low amounts of protein are detectable in normal tissues. The differential display of antigen in normal versus tumor tissues has been reported to create an opportunity to target p53 by immunotherapy. We sought to determine the relationship between p53 expression and its recognition by cognate T cells in human tumors including common epithelial malignancies. Inasmuch as nonsense or missense p53 mutations may disrupt processing and presentation, we studied tumors with either identified wild-type or mutated p53, based on our gene-sequencing studies or published data. T cells transduced with a high-affinity, p53264-272-reactive T cell receptor (TCR) derived from HLA-A2.1 transgenic mice recognized a wide panel of human tumor lines. There was no significant correlation between p53 expression in tumors and recognition by the anti-p53 TCR-transduced T cells. This conclusion was based on the study of 48 cell lines and is in contrast to several prior studies that used only a limited number of selected cell lines. A panel of normal cells was evaluated for recognition, and some of these populations were capable of stimulating anti-p53 T cells, albeit at low levels. These studies raise doubts concerning the suitability of targeting p53 in the immunotherapy of cancer patients.

Original languageEnglish (US)
Pages (from-to)1219-1231
Number of pages13
JournalHuman Gene Therapy
Volume19
Issue number11
DOIs
StatePublished - Nov 1 2008
Externally publishedYes

Fingerprint

T-Cell Antigen Receptor
T-Lymphocytes
Neoplasms
Immunotherapy
Thomsen-Friedenreich antibodies
Cell Line
Missense Mutation
Transgenic Mice
Proteins
Antigens

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Theoret, M. R., Cohen, C. J., Nahvi, A. V., Ngo, L. T., Suri, K. B., Powell, D. J., ... Rosenberg, S. A. (2008). Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells. Human Gene Therapy, 19(11), 1219-1231. https://doi.org/10.1089/hum.2008.083

Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells. / Theoret, Marc R.; Cohen, Cyrille J.; Nahvi, Azam V.; Ngo, Lien T.; Suri, Kimberly B.; Powell, Daniel J.; Dudley, Mark E.; Morgan, Richard A.; Rosenberg, Steven A.

In: Human Gene Therapy, Vol. 19, No. 11, 01.11.2008, p. 1219-1231.

Research output: Contribution to journalArticle

Theoret, MR, Cohen, CJ, Nahvi, AV, Ngo, LT, Suri, KB, Powell, DJ, Dudley, ME, Morgan, RA & Rosenberg, SA 2008, 'Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells', Human Gene Therapy, vol. 19, no. 11, pp. 1219-1231. https://doi.org/10.1089/hum.2008.083
Theoret, Marc R. ; Cohen, Cyrille J. ; Nahvi, Azam V. ; Ngo, Lien T. ; Suri, Kimberly B. ; Powell, Daniel J. ; Dudley, Mark E. ; Morgan, Richard A. ; Rosenberg, Steven A. / Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells. In: Human Gene Therapy. 2008 ; Vol. 19, No. 11. pp. 1219-1231.
@article{fe97e87e58e64acab0ce5c83136f2d1b,
title = "Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells",
abstract = "Tumor suppressor p53 is reported to be an attractive immunotherapy target because it is mutated in approximately half of human cancers, resulting in inactivation and often an accumulation of the protein in the tumor cells. Only low amounts of protein are detectable in normal tissues. The differential display of antigen in normal versus tumor tissues has been reported to create an opportunity to target p53 by immunotherapy. We sought to determine the relationship between p53 expression and its recognition by cognate T cells in human tumors including common epithelial malignancies. Inasmuch as nonsense or missense p53 mutations may disrupt processing and presentation, we studied tumors with either identified wild-type or mutated p53, based on our gene-sequencing studies or published data. T cells transduced with a high-affinity, p53264-272-reactive T cell receptor (TCR) derived from HLA-A2.1 transgenic mice recognized a wide panel of human tumor lines. There was no significant correlation between p53 expression in tumors and recognition by the anti-p53 TCR-transduced T cells. This conclusion was based on the study of 48 cell lines and is in contrast to several prior studies that used only a limited number of selected cell lines. A panel of normal cells was evaluated for recognition, and some of these populations were capable of stimulating anti-p53 T cells, albeit at low levels. These studies raise doubts concerning the suitability of targeting p53 in the immunotherapy of cancer patients.",
author = "Theoret, {Marc R.} and Cohen, {Cyrille J.} and Nahvi, {Azam V.} and Ngo, {Lien T.} and Suri, {Kimberly B.} and Powell, {Daniel J.} and Dudley, {Mark E.} and Morgan, {Richard A.} and Rosenberg, {Steven A.}",
year = "2008",
month = "11",
day = "1",
doi = "10.1089/hum.2008.083",
language = "English (US)",
volume = "19",
pages = "1219--1231",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "11",

}

TY - JOUR

T1 - Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells

AU - Theoret, Marc R.

AU - Cohen, Cyrille J.

AU - Nahvi, Azam V.

AU - Ngo, Lien T.

AU - Suri, Kimberly B.

AU - Powell, Daniel J.

AU - Dudley, Mark E.

AU - Morgan, Richard A.

AU - Rosenberg, Steven A.

PY - 2008/11/1

Y1 - 2008/11/1

N2 - Tumor suppressor p53 is reported to be an attractive immunotherapy target because it is mutated in approximately half of human cancers, resulting in inactivation and often an accumulation of the protein in the tumor cells. Only low amounts of protein are detectable in normal tissues. The differential display of antigen in normal versus tumor tissues has been reported to create an opportunity to target p53 by immunotherapy. We sought to determine the relationship between p53 expression and its recognition by cognate T cells in human tumors including common epithelial malignancies. Inasmuch as nonsense or missense p53 mutations may disrupt processing and presentation, we studied tumors with either identified wild-type or mutated p53, based on our gene-sequencing studies or published data. T cells transduced with a high-affinity, p53264-272-reactive T cell receptor (TCR) derived from HLA-A2.1 transgenic mice recognized a wide panel of human tumor lines. There was no significant correlation between p53 expression in tumors and recognition by the anti-p53 TCR-transduced T cells. This conclusion was based on the study of 48 cell lines and is in contrast to several prior studies that used only a limited number of selected cell lines. A panel of normal cells was evaluated for recognition, and some of these populations were capable of stimulating anti-p53 T cells, albeit at low levels. These studies raise doubts concerning the suitability of targeting p53 in the immunotherapy of cancer patients.

AB - Tumor suppressor p53 is reported to be an attractive immunotherapy target because it is mutated in approximately half of human cancers, resulting in inactivation and often an accumulation of the protein in the tumor cells. Only low amounts of protein are detectable in normal tissues. The differential display of antigen in normal versus tumor tissues has been reported to create an opportunity to target p53 by immunotherapy. We sought to determine the relationship between p53 expression and its recognition by cognate T cells in human tumors including common epithelial malignancies. Inasmuch as nonsense or missense p53 mutations may disrupt processing and presentation, we studied tumors with either identified wild-type or mutated p53, based on our gene-sequencing studies or published data. T cells transduced with a high-affinity, p53264-272-reactive T cell receptor (TCR) derived from HLA-A2.1 transgenic mice recognized a wide panel of human tumor lines. There was no significant correlation between p53 expression in tumors and recognition by the anti-p53 TCR-transduced T cells. This conclusion was based on the study of 48 cell lines and is in contrast to several prior studies that used only a limited number of selected cell lines. A panel of normal cells was evaluated for recognition, and some of these populations were capable of stimulating anti-p53 T cells, albeit at low levels. These studies raise doubts concerning the suitability of targeting p53 in the immunotherapy of cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=57049101021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57049101021&partnerID=8YFLogxK

U2 - 10.1089/hum.2008.083

DO - 10.1089/hum.2008.083

M3 - Article

C2 - 19848582

AN - SCOPUS:57049101021

VL - 19

SP - 1219

EP - 1231

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 11

ER -